• Explore /
  • Poster
  • / A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).

A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).

Abstract Video & Slides Poster

Authors

null

Sara M. Tolaney

Dana-Farber Cancer Institute, Boston, MA

Sara M. Tolaney , Kevin Kalinsky , Virginia G. Kaklamani , David R. D'Adamo , Gursel Aktan , Michaela L. Tsai , Ruth O'Regan , Peter A. Kaufman , Sharon Wilks , Eleni Andreopoulou , Debra A. Patt , Yuan Yuan , Grace Wang , Dongyuan Xing , Ella Kleynerman , Vassiliki Karantza , Sami Diab

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02513472

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1015)

DOI

10.1200/JCO.2020.38.15_suppl.1015

Abstract #

1015

Poster Bd #

100

Abstract Disclosures

Similar Posters

First Author: Neelima Vidula

First Author: Benjamin Garrett Vincent

First Author: Gauri R. Varadhachary

First Author: Thierry Landre